期刊
CLINICAL CANCER RESEARCH
卷 12, 期 2, 页码 328-331出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-05-2543
关键词
-
类别
资金
- NCI NIH HHS [P30 CA 043703, R01 CA 63193, R01 CA 86257] Funding Source: Medline
- NIA NIH HHS [R01 AG 024916] Funding Source: Medline
O-6-Methylguanine DNA methyltransferase (MGMT) has been studied for >20 years as a gene that is associated with the mulagenicity and cytotoxicity induced by either methylating carcinogens or alkylating (methylating and chloroethylating) therapeutic agents. Pioneering studies of alkylating agents identified alkylated guanine at the O-6 position, the substrate of MGMT, as a potentially promutagenic and lethal toxic DNA lesion. MGMT plays a prominent role in DNA adduct repair that limits the mutagenic and cytotoxic effect of alkylating agents. Because of its role in cancer etiology and chemotherapy resistance, MGMT is of particular interest. In this article, the clinical effect of MGMT expression and targeted modulation of MGMT will be summarized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据